Literature DB >> 18613832

Strategies for use of IL-10 or its antagonists in human disease.

Anne O'Garra1, Franck J Barrat, Antonio G Castro, Alain Vicari, Catherine Hawrylowicz.   

Abstract

SUMMARY: Interleukin-10 (IL-10) is a cytokine with broad anti-inflammatory properties by its suppression of both macrophage and dendritic cell function, including antigen-presenting cell function and the production of proinflammatory cytokines. This can result subsequently in the feedback regulation of both T-helper 1 (Th1)-type and Th2-type responses. This review discusses the potential use of IL-10 or agents that induce IL-10 as potential anti-inflammatory therapies in inflammatory diseases. Although IL-10-deficient mice develop colitis in the presence of normal gut flora and clear certain intracellular pathogens more efficiently, this is often accompanied by immunopathology, which can be lethal to the host. This reinforces the anti-inflammatory properties of IL-10, although it should be noted that as discussed below, IL-10 can also promote B-cell and other immune responses under particular settings. A penalty of its role to limit the immune and inflammatory responses to pathogens and prevent damage to the host is that high or dysregulated levels of IL-10 may result in chronic infection. Thus, antagonists of IL-10 show great potential as adjuvants in preventative or therapeutic vaccines against chronic infection or cancer. This article reviews basic published studies on IL-10, which may lead to potential uses of IL-10 or its antagonists in human disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18613832     DOI: 10.1111/j.1600-065X.2008.00635.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  171 in total

Review 1.  Emerging roles of T helper subsets in the pathogenesis of asthma.

Authors:  Douglas M Durrant; Dennis W Metzger
Journal:  Immunol Invest       Date:  2010       Impact factor: 3.657

2.  IL-10 inhibits miR-155 induction by toll-like receptors.

Authors:  Claire E McCoy; Frederick J Sheedy; Joseph E Qualls; Sarah L Doyle; Susan R Quinn; Peter J Murray; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2010-04-30       Impact factor: 5.157

Review 3.  Cytokines that target immune killer cells against tumors.

Authors:  Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2020-06-10       Impact factor: 11.530

4.  IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Authors:  Zhaojun Sun; Julien Fourcade; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; John M Kirkwood; Hassane M Zarour
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

5.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

Review 6.  Location, location, location: tissue-specific regulation of immune responses.

Authors:  Wei Hu; Chandrashekhar Pasare
Journal:  J Leukoc Biol       Date:  2013-07-03       Impact factor: 4.962

7.  Overcoming obstacles to the effective immunotherapy of human cancer.

Authors:  Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

8.  RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels.

Authors:  Anne L Astier; Gaëlle Beriou; Thomas M Eisenhaure; Stephen M Anderton; David A Hafler; Nir Hacohen
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

Review 9.  Cell type-specific regulation of IL-10 expression in inflammation and disease.

Authors:  Christian M Hedrich; Jay H Bream
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

10.  FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.

Authors:  Chang Liu; Zhi Li; Shuo Wang; Yibo Fan; Simeng Zhang; Xianghong Yang; Kezuo Hou; Jianhua Tong; Xuejun Hu; Xiaonan Shi; Xiaoxun Wang; Yunpeng Liu; Xiaofang Che; Xiujuan Qu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.